Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Merck

KEYTRUDA drives growth in 2016

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
 
4Q Revenues: $10.1 billion (-1%)

4Q Earnings: $1.2 billion (+21%)

FY Revenues: $39.8 billion (+1%)

FY Earnings: $5.7 billion (+28%)

Comments: KEYTRUDA sales were up 148% to $1.4 billion for the year driven by new indications and new markets. JANUVIA/JANUMET sales were $6.1 billion, up 2% for the year. ZETIA/VYTORIN sales were down 2% to $3.7 billion. GARDASIL/GARDASIL 9 sales were up 14% to $2.2 billion due to increased pricing and demand in the U.S. PROQUAD, M-M-R II and VARIVAX sales were up 9% to $1.6 billion. ISENTRESS sales were down 6% to $1.4 billion for the year. REMICADE sales declined 29% to $1.3 billion due to biosimilar competition in Europe. CUBICIN sales were down 4% to $1.1 billion. SINGULAIR sales were down 4% to $915 million. PNEUMOVAX 23 sales were up 18% to $641 million due to the adoption of recently issued vaccination guidelines from the CDC. Animal Health sales were up 4% to $3.5 billion for the year. 4Q and FY15 results included a $680 million charge related to the settlement of VIOXX shareholder class action litigation.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters